Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

Dermatomyositis Companies are AstraZeneca., Bristol-Myers Squibb Company, Pfizer, Octapharma AG, Corbus Pharmaceuticals, Holdings., Ermium Therapeutics, Kezar Life Sciences, Neovacs, Horizon Therapeutics, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Japan Blood Products Organization, Mallinckrodt, Genentech, Astellas Pharma, Biogen, and others
(Albany, USA) DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Dermatomyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dermatomyositis market size from 2020 to 2034, segmented by seven major markets. The Dermatomyositis Market Report also covers current Dermatomyositis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dermatomyositis market.

To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Dermatomyositis Market Report:

* The Dermatomyositis market size was valued approximately USD 230 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
* In February 2025, NovelMed Therapeutics, a clinical-stage biotechnology company, pioneering complement-targeting therapies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted clearance for Ruxoprubart (NM8074), an investigational drug, to begin an efficacy Phase II trial to treat Dermatomyositis (DM), a rare autoimmune disorder.
* In December 2024, RESTEM, a clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies to modulate the immune system, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its umbilical cord outer lining stem cells (ULSCs) program for the treatment of Polymyositis (PM) and Dermatomyositis (DM).
* In September 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM).
* In July 2024, Priovant Therapeutics announced that it had completed enrollment for the Phase 3 VALOR study assessing brepocitinib in dermatomyositis. This study has included 241 participants from 90 locations across four continents, marking it as the largest interventional trial for dermatomyositis ever undertaken.
* In the US, the highest incidence of cases occurred within the 40-59 age bracket, followed by the 60-79, 18-39, and 0-17 age brackets. Conversely, the lowest incidence was observed in the greater than or equal to 80 age group, with approximately 14,600, 13,000, 5,000, 4,000, and 1,500 cases, respectively, in 2023.
* DelveInsight's estimates indicate that among EU4 and the UK, Germany held the largest market share for dermatomyositis, reaching nearly USD 15 million in 2023, followed by the UK with almost USD 13 million in the same year. Conversely, Spain had the smallest market share, totaling around USD 9 million.
* As per DelveInsight's assessment, the total diagnosed prevalent cases of dermatomyositis in the 7MM were roughly 71,000 in 2023. These numbers are projected to rise over the forecast period from 2024 to 2032.
* In 2023, the US had the highest number of diagnosed prevalent cases of dermatomyositis among the 7MM, totaling approximately 38,000 cases, followed by Japan with nearly 12,000 cases.
* In 2023, the age-specific diagnosed prevalent cases of dermatomyositis showed the highest numbers in the 4059 and 6079 age groups, with approximately 25,000 cases in each group among the 7MM.
* In the US, the highest number of cases were observed in the 40-59 age group, followed by the 60-79, 18-39, and 0-17 age groups, while the lowest number of cases were reported for the greater than or equal to 80 age group. Specifically, there were nearly 14,600, 13,000, 5,000, 4,000, and 1,500 cases, respectively, in 2023.
* Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Neovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
* Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
* The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)
* The Dermatomyositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.

Dermatomyositis Overview

Dermatomyositis is a rare inflammatory myopathy characterized by muscle weakness and distinctive skin manifestations. This autoimmune disease primarily affects proximal muscles, leading to progressive muscle weakness in the shoulders, hips, and neck. Dermatomyositis symptoms include heliotrope rash (purplish discoloration around the eyes), Gottron's papules (red, scaly patches on knuckles), and photosensitivity. Patients often experience difficulty in climbing stairs, lifting objects, or rising from a seated position due to muscle inflammation.

The exact cause of dermatomyositis remains unclear, but it is believed to involve immune system dysfunction, genetic predisposition, and environmental triggers. Diagnosis involves clinical evaluation, muscle biopsy, electromyography (EMG), and elevated muscle enzymes such as creatine kinase (CK). Magnetic resonance imaging (MRI) and antibody tests, including anti-Mi-2, anti-TIF1-, and anti-NXP2, help in confirming dermatomyositis.

Treatment options for dermatomyositis include corticosteroids, immunosuppressants, and biologics like rituximab. Physical therapy and skin care are essential for managing symptoms. In some cases, dermatomyositis is associated with malignancies, necessitating cancer screening. While treatment helps control muscle inflammation and skin disease, long-term monitoring is crucial to prevent complications such as interstitial lung disease. Early diagnosis and aggressive treatment improve the prognosis for dermatomyositis patients.

Get a Free sample for the Dermatomyositis Market Report @ [https://www.delveinsight.com/report-store/dermatomyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Dermatomyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dermatomyositis Epidemiology Segmentation:

The Dermatomyositis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Dermatomyositis
* Prevalent Cases of Dermatomyositis by severity
* Gender-specific Prevalence of Dermatomyositis
* Diagnosed Cases of Episodic and Chronic Dermatomyositis

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ [https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Dermatomyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to get launched during the study period. The analysis covers Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dermatomyositis Therapies and Key Companies

* Brepocitinib: Priovant Therapeutics, Inc.
* Lenabasum: Corbus Pharmaceuticals
* HIZENTRA: CSL Behring
* Ravulizumab: Alexion
* Lenabasum: Corbus Pharmaceuticals Inc.
* IMO-8400: Idera Pharmaceuticals
* GLPG3667: Galapagos NV
* M5049: EMD Serono
* human immunoglobulin G: CSL Behring
* PF-06823859: Pfizer
* Octagam: Octapharma
* KZR-616: Kezar Life Sciences, Inc.
* GB-0998: Japan Blood Products Organization
* H.P. Acthar Gel: Mallinckrodt
* Adrenocorticotropic Hormone Gel: Mallinckrodt
* tocilizumab: Genentech, Inc.
* Tacrolimus: Astellas Pharma Inc
* Rituximab: Biogen

Discover more about therapies set to grab major Dermatomyositis market share @ [https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Dermatomyositis Market Strengths

* A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAs targeting C5 complement, IFN1, FcRn, and others.
* Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients

Dermatomyositis Market Opportunities

* Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression.
* The lack of curative and effective therapies allows pharma players to conduct trials and bring novel, disease-modifying therapies.

Scope of the Dermatomyositis Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Neovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
* Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
* Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
* Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement

To know more about Dermatomyositis companies working in the treatment market, visit @ [https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Dermatomyositis Market Report Introduction

2. Executive Summary for Dermatomyositis

3. SWOT analysis of Dermatomyositis

4. Dermatomyositis Patient Share (%) Overview at a Glance

5. Dermatomyositis Market Overview at a Glance

6. Dermatomyositis Disease Background and Overview

7. Dermatomyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Dermatomyositis

9. Dermatomyositis Current Treatment and Medical Practices

10. Dermatomyositis Unmet Needs

11. Dermatomyositis Emerging Therapies

12. Dermatomyositis Market Outlook

13. Country-Wise Dermatomyositis Market Analysis (2020-2034)

14. Dermatomyositis Market Access and Reimbursement of Therapies

15. Dermatomyositis Market Drivers

16. Dermatomyositis Market Barriers

17. Dermatomyositis Appendix

18. Dermatomyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dermatomyositis-drug-market-2034-clinical-trials-ema-pdma-fda-approvals-treatment-market-prevalence-medication-statistics-therapies-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.